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Abstract K-Toxins from scorpion venoms prolong the action
potential of excitable cells by blocking sodium channel inactiva-
tion. We have purified bukatoxin, an K-toxin from scorpion
(Buthus martensi Karsch) venom, to homogeneity. Bukatoxin
produced marked relaxant responses in the carbachol-precon-
tracted rat anococcygeus muscle (ACM), which were mediated
through the L-arginine^nitric oxide synthase^nitric oxide path-
way, consequent to a neuronal release of nitric oxide. Based on
the presence of proline residues in the flanking segments of
protein^protein interaction sites, we predicted the site between
52PP56 to be the potential interaction site of bukatoxin. A
homology model of bukatoxin indicated the presence of this site
on the surface. Buka11, a synthetic peptide designed based on
this predicted site, produced a concentration-dependent nitric
oxide-mediated relaxant response in ACM. Using alanine-
substituted peptides, we have shown the importance 53DKV55
flanked by proline residues in the functional site of buka-
toxin. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Scorpion venoms are well-known sources of neurotoxins.
Most of these toxins a¡ect voltage-gated sodium channels
that are responsible for the depolarization phase of the action
potential in excitable cells [1]. These sodium channel toxins
are single-chain polypeptides composed of 60^70 amino acid
residues linked by four disul¢de bridges [2]. They are classi¢ed
into two groups based on their pharmacological e¡ect on the
kinetics of sodium channels. K-Toxins bind to site 3 and pro-
long the action potential by blocking sodium channel in-
activation [3^5], while L-toxins bind to site 4 and shift the
voltage of activation towards more negative potentials there-
by a¡ecting the sodium channel activation leading to sponta-
neous and repetitive ¢ring [5,6]. The interaction of L-toxins
is voltage-independent, unlike the voltage-dependent inter-
action of K-toxins. However, they have similar three-dimen-
sional structures; they are K/L proteins with one or two
short segments of K-helices and a triple-stranded L-sheet,
connected by variable regions forming loops [7]. Thus, this
structural similarity and functional divergence in sodium
channel toxins is intriguing. Based on structural comparison,
chemical modi¢cations and site-directed mutagenesis, a multi-
site interaction for the K-toxin receptor has been suggested
[8^11]. However, the site(s) involved in molecular recognition
and binding of sodium channel toxins are yet to be identi-
¢ed.
Protein^protein interactions are highly speci¢c and are due
to molecular recognition sites. Proline residues have a hypo-
thetical structural role in the £anking segments of interaction
sites [12,13]. They act as barriers between the interaction site
and their neighboring secondary structural elements in pro-
tecting its integrity and conformation. They also help in the
presentation of the interaction site to its complementary pro-
tein and thus facilitate protein^protein interaction [12,13].
Based on this principle, Kini and Evans [14] developed a
method to identify protein^protein interaction sites directly
from the amino acid sequences. Using this method, protein^
protein interaction sites in several proteins that are unrelated
in their structure, function and phylogeny have been identi¢ed
[15,16].
In this paper we report the puri¢cation, characterization
and determination of the complete amino acid sequence of
bukatoxin, a 65-residue peptide from Buthus martensi Karsch
venom and the identi¢cation of the tripeptide, 53DKV55 that
could contribute to the function of the toxin.
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2. Materials and methods
2.1. Materials
Lyophilized B. martensi Karsch venom was obtained from the
Huazhen Pharmaceutical Animal Research Institute (Guangzhou,
China). Prepacked Superdex 75 and Sephasil C18 columns were
from Pharmacia Biotech (Uppsala, Sweden). Sprague^Dawley rats
(280^350 g) were from the Animal Holding Unit, National University
of Singapore. Acetonitrile (ACN) and tri£uoroacetic acid (TFA) were
purchased from Fisher Scienti¢c (Leicestershire, UK) and Fluka
Chemika-Biochemika (Buchs, Switzerland), respectively. K-Cyano-4-
hydroxycinnamic acid and all reagents for peptide synthesis and se-
quencing were purchased from Perkin-Elmer Applied Biosystems
(Chiba, Japan). Drugs and chemicals used for pharmacological studies
were from Sigma Chemicals (St. Louis, MO, USA).
2.2. Puri¢cation of bukatoxin
Bukatoxin was puri¢ed from the crude venom by gel ¢ltration and
reverse-phase high-performance liquid chromatography (HPLC). The
lyophilized crude venom was applied on to a Superdex 75 Hiload
(16/60) column equilibrated with 50 mM Tris bu¡er pH 7.5. Proteins
eluted were monitored at 280 nm. The biologically active fraction was
then applied onto a Sephasil C18 reverse-phase column, equilibrated
with 0.1% TFA. The bound peptides were eluted using a linear gra-
dient of ACN. Elution was monitored at 215 nm.
2.3. Electrospray ionization mass spectrometry (ESI/MS) and
capillary electrophoresis (CE)
Samples were analyzed using Perkin-Elmer Sciex API 300 triple
quadrupole mass spectrometry equipped with an ion spray interface
(Sciex, Thronton, Canada). The ion spray voltage was set at 4600 V
and the ori¢ce voltage was set at 30 V. The mass was determined by
£ow injection analysis at a £ow rate of 50 Wl/min using Shimadzu 10
AD pumps as the solvent delivery system. CE was performed on a
BioFocus 3000 system (Bio-Rad, Singapore). The sample was injected
to a 25 WmU24 cm coated capillary using pressure mode (5 psi/s) and
run in 0.1 M phosphate bu¡er (pH 2.5) under 12.00 kV from + to 3
at 15‡C for 10 min. Migration was monitored at 200 nm.
2.4. N-terminal amino acid sequence
The N-terminal amino acid sequence of the peptide was determined
by automated Edman degradation using an Applied Biosystem 494
pulsed liquid-phase sequencer equipped with an online 785A PTH
amino acid analyzer.
2.5. Pharmacological studies
The pair of anococcygeus muscles (ACM) from male Sprague^
Dawley rats was isolated and mounted under 1 g resting tension in
a 4-ml organ bath containing Krebs physiological salt solution [17].
The solution was maintained at 37‡C and aerated with 5% carbon
dioxide in oxygen. Carbachol (CCh) 3 WM was used to increase the
tone of the ACM, which was pretreated with 5 WM of phentolamine
to block the adrenergic response. Relaxant responses of the CCh-
precontracted ACM were evoked by electrical ¢eld stimulation
(EFS) (20^30 V, 1 ms, 10 Hz for 10 s) using a Grass stimulator
(Model S88) and the data were recorded in a MacLab system81 via
a force-displacement transducer (model FT03). The e¡ects of tetrodo-
toxin (TTX) 2 WM, nitro-L-arginine methyl ester hydrochloride (L-
NAME) 50 WM, D-NAME 50 WM, 1H-(1,2,4)oxadiazolo(4,3-a)qui-
noxalin-1-one (ODQ) 1 WM or hemoglobin (Hb) 1 WM on the relaxant
responses of the ACM produced by bukatoxin (0.001^3 WM), buka11
(1^200 WM), EFS or sodium nitroprusside (SNP) 1 WM were studied.
2.6. Molecular modeling
The three-dimensional structure of Leiurus quinquestriatus hebraeus
toxin (PDB ID: 1LQI) and Androctonus australis hector toxin (1AHO)
were used as homology templates for molecular modeling of bukatox-
in. The sequence was submitted to the PredictProtein server for sec-
ondary structure prediction [18,19] and the information from the Pre-
dictProtein was used to check the homology match. The ¢rst NMR
structure of 1LQI (out of 29) was structurally aligned with the crystal
structure of 1AHO. The pair-wise sequence identities between buka-
toxin and the templates were 66% and 64% respectively. The homol-
ogy model was constructed using the automated MODELER routine
(Insight II, Molecular Simulations Inc., USA). Since this version of
MODELER ¢ts only the backbone, the side chains were re-packed
using the rotamer library supplied by Insight. Except for the loop
regions where the accuracy of the backbone atoms is expected to be
lower, the side chains are positioned well by this packing procedure.
Finally the model was re¢ned by energy minimization using molecular
mechanics.
2.7. Peptide synthesis
Buka11 (YKLPDKVPIRV), scrambled peptide (YPKPVRDIKVL)
Fig. 1. Puri¢cation and homogeneity of bukatoxin. A: Gel ¢ltration
of B. martensi Karsch venom on a Superdex 75 column equilibrated
with 50 mM Tris bu¡er. The crude venom (200 mg) was dissolved
in 1 ml of 50 mM Tris bu¡er and centrifuged at 3000 rpm for 10
min. Supernatant was then loaded onto the column. Elution was
monitored at 280 nm. B: Reverse-phase HPLC of fraction 4 on a
Sephasil C18 column. The column was equilibrated with 0.1% TFA
and eluted with a linear gradient of 80% acetonitrile in 0.1% TFA.
Elution was monitored at 215 nm. The horizontal bars indicate
pooled peaks. C: The mass spectrum determined by ESI/MS shows
multiple charged ions related to molecules bearing four and ¢ve
protons. Inset shows the electropherogram of bukatoxin as deter-
mined by CE.
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and the three alanine analogues (D5A Buka11; K6A Buka11 and
V7A Buka11) were synthesized by solid-phase methodology using 9-
£uorenylmethoxycarbonyl chemistry on an Applied Biosystems model
433A peptide synthesizer and were puri¢ed by HPLC. The puri¢ed
synthetic peptides were characterized by matrix-assisted laser desorp-
tion/ionization time of £ight mass spectrometry measurements.
3. Results and discussion
The fractionation of the crude venom on a Superdex 75 gel
¢ltration column yielded ¢ve fractions (Fig. 1A). Among these
fractions, only fraction four was found to mediate relaxation
responses in the precontracted rat ACM. This fraction was
then further sub-fractionated by reverse-phase HPLC into
four major peaks (Fig. 1B). Of the four peaks, peak two
was found to possess pharmacological activity. Homogeneity
of the toxin was assessed by ESI/MS and CE (Fig. 1C). The
molecular weight of the toxin was found to be 7215.6 þ 0.16.
This toxin was named bukatoxin. The complete amino acid
sequence of bukatoxin (SwissProt accession number P82815)
was determined by automated Edman degradation, with a
reproducible yield of 95%. During sequencing, blank cycles
were encountered at positions 12, 16, 22, 26, 36, 46, 48 and
63. With cysteines at these positions, the calculated molecular
weight was 7215.0, which matched the observed molecular
weight. Bukatoxin shows a striking structural identity of
78% with neurotoxin X from Mesobuthus eupeus [20] and
72% with neurotoxin IV from L. quinquestriatus quinquestria-
tus [21]. The sequence alignment of bukatoxin with other
scorpion toxins is given in Fig. 2.
Bukatoxin produced a marked, concentration-dependent re-
laxation of the CCh-precontracted rat ACM (Fig. 3). The
bukatoxin-mediated relaxant responses, like those produced
by EFS, were completely inhibited by L-NAME (Fig. 3A),
TTX (Fig. 4A), ODQ (Fig. 4B) and Hb but not by D-
NAME. In contrast, the relaxation induced by the nitric oxide
(NO) donor SNP was inhibited only by ODQ and Hb and not
by L-NAME, D-NAME or TTX.
The relaxant responses produced by EFS in the ACM were
sensitive to inhibition by TTX, a highly selective blocker of
neuronal sodium channels [34], indicating that EFS activated
neuronal sodium channels with consequent depolarization of
nitrergic nerves and the release of NO. Similarly, the relaxant
responses produced by bukatoxin also involve a neuronal re-
lease of NO since TTX inhibited these responses. It is likely
that bukatoxin mediates this action by modulation of neuro-
nal sodium channels. Furthermore, our results provide strong
evidence that the bukatoxin-mediated relaxant responses of
Fig. 2. Sequence identities of bukatoxin with other scorpion K- [20^27] and L-toxins [28^33]. Sequences were aligned with cysteine residues and
gaps (^) were introduced for maximum accuracy. % I is the percentage identity of BKTx (bukatoxin) with other scorpion K- and L-toxins.
Fig. 3. A: Bukatoxin (0.2 WM) evoked a marked relaxation of the
CCh (3 WM)-precontracted rat ACM. B: Concentration^response ef-
fect of bukatoxin and Buka11.
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the ACM, like those to EFS, are mediated through the acti-
vation of the L-arginine^nitric oxide synthase (NOS)^NO
pathway since the stereoselective and competitive NOS inhib-
itor L-NAME, but not its D-isomer, produced complete inhi-
bition of these relaxant responses. The binding and sequestra-
tion of NO by Hb [35] may account for the inhibition of the
bukatoxin-mediated relaxation by Hb. Moreover, the relaxant
responses produced by bukatoxin were inhibited by ODQ, a
selective inhibitor of NO-sensitive soluble guanylyl cyclase
[36], suggesting the NO^cGMP pathway underlies these relax-
ant responses and that the target enzyme for NO in the ACM
is soluble guanylyl cyclase.
To identify the functional site of the sodium channel neuro-
toxins, we used a method of identifying potential interaction
sites based on the presence of proline residues in the £anking
segments of protein^protein interaction sites [11,12]. Accord-
ingly, we aligned the amino acid sequences of K- and L-toxins
and identi¢ed the region between 52 and 56, particularly the
tripeptide segment 53DKV55, as the possible interaction site of
K-toxins (Fig. 2). Inspection of the molecular model of buka-
toxin revealed that this site forms a surface loop and is avail-
able for binding interaction (Fig. 5A). This site is independent
of face A, face B and site C as proposed by De-Cheng [8].
Therefore we predicted that this segment, in particular
53DKV55, might be functionally important in K-toxins. On
the other hand, this tripeptide segment is replaced in all
L-toxins (Fig. 2). Overall, K-toxins have a characteristic site
that is di¡erent from L-toxins.
Based on this predicted site, we synthesized the peptide
Buka11, and examined its activity. Buka11, but not the
scrambled peptide, produced concentration-dependent relax-
ant responses in the CCh-precontracted ACM (Figs. 3B and
4C), which were sensitive to inhibition by TTX, L-NAME,
ODQ and Hb. These results indicate that the predicted seg-
ment could probably play a signi¢cant role in the interaction
with the neuronal sodium channel. Further, each of the three
alanine-substituted analogues of Buka11 failed to produce any
relaxant response in the ACM even at a concentration of
1 mM, implying that the three residues (DKV) could play a
vital role in peptide^channel interaction. The activity of
Buka11 was, however, V800-fold less than that of the native
toxin. This lower activity is probably due to the conforma-
tional £exibility of the short peptide. This is the ¢rst evidence
for the role of the 52PDKVP56 loop in the interaction site of
Fig. 4. The relaxant e¡ects of bukatoxin (0.2 WM) and EFS (20^30 V, 1 ms, 10 Hz for 10 s) on the precontracted ACM were completely inhib-
ited by (A) TTX (2 WM) and (B) ODQ (1 WM). SNP (1 WM) produced a marked relaxation of the ACM when added at the end of each experi-
ment, indicating that the muscle remained viable to nitrergic relaxation throughout the experiment. C: The relaxant e¡ect of Buka11.
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sodium channel toxins from scorpion venoms. In addition, it
is possible that other residues in the vicinity, for example Val1
and Asp9, which are also part of the same surface (Fig. 5B),
could contribute to the interaction. Similarly, short segments
or a few residues have been reported to be su⁄cient for spe-
ci¢c recognition and interaction between toxins and their tar-
get ion channels [15,37,38].
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Fig. 5. A: Molecular model of bukatoxin. The regions with lower
homology are shown in thick ribbon. The predicted site 52PP56 is
highlighted black. B: Proposed surface of bukatoxin that may inter-
act with the sodium channel. Based on the surface accessibility, it is
proposed that along with the site 52PP56, Val1 and Asp9 may also
be responsible for the interaction of the toxin to sodium channel
protein.
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